Efforts Underway To Lower Cost Of New Hepatitis C Drug

Two Reuters articles discuss efforts to lower the cost of a new hepatitis C treatment.

Reuters: Gilead aims to license hepatitis C drug to 3-4 Indian firms
“Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations…” (Hirschler, 4/8).

Reuters: WHO joins clamor to make new hepatitis C pills affordable
“The World Health Organization wants a ‘concerted effort’ to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide…” (Hirschler, 4/9).